Cargando…

Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers

BACKGROUND: Vaccine-induced population immunity is a key global strategy to control coronavirus disease 2019 (COVID-19). The rapid implementation and availability of several COVID-19 vaccines is now a global health-care priority but more information about humoral responses to single- and double-dose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Padoan, Andrea, Dall'Olmo, Luigi, Rocca, Foscarina della, Barbaro, Francesco, Cosma, Chiara, Basso, Daniela, Cattelan, Annamaria, Cianci, Vito, Plebani, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056941/ https://www.ncbi.nlm.nih.gov/pubmed/33857476 http://dx.doi.org/10.1016/j.cca.2021.04.006

Ejemplares similares

SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays
por: Padoan, Andrea, et al.
Publicado: (2021)

Two rapid SARS-CoV-2 disposable devices for semi-quantitative S-RBD antibody levels determination compared with CLIA and ELISA assays at different protective thresholds
por: Padoan, Andrea, et al.
Publicado: (2022)

Clinical performances of an ELISA for SARS-CoV-2 antibody assay and correlation with neutralization activity
por: Padoan, Andrea, et al.
Publicado: (2020)

Salivary SARS-CoV-2 antigen rapid detection: A prospective cohort study
por: Basso, Daniela, et al.
Publicado: (2021)

Emergency department and early detection of adolescents and young adults at risk of developing mental disorders: an exploratory study
por: Solmi, Marco, et al.
Publicado: (2020)

The Interplay between Nevi and Melanoma Predisposition Unravels Nevi-Related and Nevi-Resistant Familial Melanoma
por: Pellegrini, Stefania, et al.
Publicado: (2021)

Immunogenicity trends 1 and 3 months after second BNT162B2 vaccination among healthcare workers in Israel
por: Shachor-Meyouhas, Yael, et al.
Publicado: (2022)

Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea
por: Lee, Yun Woo, et al.
Publicado: (2021)

Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers
por: Lange, Bettina, et al.
Publicado: (2021)

IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study
por: Padoan, Andrea, et al.
Publicado: (2020)

Effectiveness of BNT162b2 vaccine against SARS-CoV-2 among healthcare workers
por: Sansone, Emanuele, et al.
Publicado: (2021)

Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
por: Robertson, John F R, et al.
Publicado: (2021)

The University of Padua salivary-based SARS-CoV-2 surveillance program minimized viral transmission during the second and third pandemic wave
por: Basso, Daniela, et al.
Publicado: (2022)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
por: Zurac, Sabina, et al.
Publicado: (2022)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
por: Çulpan, Hazal Cansu, et al.
Publicado: (2023)

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
por: Redjoul, Rabah, et al.
Publicado: (2021)

Inflammation and Pancreatic Cancer: Focus on Metabolism, Cytokines, and Immunity
por: Padoan, Andrea, et al.
Publicado: (2019)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose
por: Vicenti, Ilaria, et al.
Publicado: (2021)

Salivary proteomic analysis in asymptomatic and symptomatic SARS-CoV-2 infection: Innate immunity, taste perception and FABP5 proteins make the difference
por: Aita, Ada, et al.
Publicado: (2022)

Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
por: Cocomazzi, Giovanna, et al.
Publicado: (2021)

Acute Myocarditis Following the Administration of the Second BNT162b2 COVID-19 Vaccine Dose
por: Miqdad, Mohammed A, et al.
Publicado: (2021)

DIAPHRAGMATIC PARALYSIS FOLLOWING SECOND DOSE OF THE BNT162B2 MRNA COVID-19 VACCINE
por: PRUDENTI, JOHN A, et al.
Publicado: (2022)

Dynamics of anti-Spike IgG antibody level after the second BNT162b2 COVID-19 vaccination in health care workers
por: Ikezaki, Hiroaki, et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
por: Ferrari, Davide, et al.
Publicado: (2021)

Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers
por: Campo, Flaminia, et al.
Publicado: (2021)

Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare Workers
por: Vassilaki, Niki, et al.
Publicado: (2021)

Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers
por: Núñez López, Concepción, et al.
Publicado: (2023)

Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers
por: Núñez López, Concepción, et al.
Publicado: (2023)

A case of reactivation of varicella–zoster virus after BNT162b2 vaccine second dose?
por: Santovito, Luca Spiro, et al.
Publicado: (2021)

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
por: Shrotri, Madhumita, et al.
Publicado: (2021)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
por: Barocci, Simone, et al.
Publicado: (2022)

SARS-CoV-2 Infection in Spondyloarthritis Patients Treated With Biotechnological Drugs: A Study on Serology
por: Ortolan, Augusta, et al.
Publicado: (2021)

The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects
por: Vicenti, Ilaria, et al.
Publicado: (2021)

Alpha-melanocyte stimulating hormone (α-MSH): biology, clinical relevance and implication in melanoma
por: Dall’Olmo, Luigi, et al.
Publicado: (2023)

Gender-specific associations between polymorphisms of the circadian gene RORA and cutaneous melanoma susceptibility
por: Benna, Clara, et al.
Publicado: (2021)

Decline of immune humoral response after BNT162b2 vaccine
por: Ferri, Sonia, et al.
Publicado: (2022)

BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers
por: Benenson, Shmuel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f2rmfbchimi3nv4v9vdnhtngkm